Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

James Legg's Biography



James Legg, Senior Vice President of Research, Crescendo Biologics

James Legg Ph.D. is SVP Research at Crescendo Biologics where he is responsible for managing Crescendo’s Immuno Oncology Portfolio from research through to preclinical development as well as the biology/pharmacology functions. James has 15 years’ experience in biologics drug discovery, mostly in the oncology area and has been responsible for the successful progression of multiple oncology biologics programmes through the research phases of drug discovery. Prior to joining Crescendo, James was a member of the oncology leadership team at MedImmune, the Biologics arm of AstraZeneca and held key scientific positions at Cambridge Antibody Technology. James has a BSc in Applied Biology from Bath University, a Ph.D in Molecular Cell Biology from Imperial College, London and undertook PostDoctoral research at Imperial Cancer Research Fund (Now CRUK) in London.

James Legg Image

CB307: A Novel CD137/4-1BB Agonist Humabody Therapeutic for PSMA-Positive Tumours

Monday, 28 October 2019 at 16:30

Add to Calendar ▼2019-10-28 16:30:002019-10-28 17:30:00Europe/LondonCB307: A Novel CD137/4-1BB Agonist Humabody Therapeutic for PSMA-Positive TumoursImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

  • Crescendo Biologics has initiated pre-clinical development of CB307, a novel trispecific Humabody VH targeting CD137 (4-1BB), prostate specific membrane antigen (PSMA) and human serum albumin (HSA)
  • The talk will describe the identification, mechanism of action and preclinical characterisation of CB307
  • The benefits of using the modular Humabody VH platform, rather than an IgG format to develop this molecule will be discussed, including optimal (monovalent) engagement of both targets with small VH domains and the avoidance of Fc receptor interactions
  • The unique design of CB307 enables highly potent and tumour selective T-cell co-stimulation


Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com